Antibody-drug conjugate · Cytotoxic, directed at AXL receptor tyrosine kinase (AXL) · developed by ADC Therapeutics
Mipasetamab uzoptirine is an antibody-drug conjugate consisting of a humanized anti-AXL monoclonal antibody conjugated to SG3199, a cytotoxic pyrrolobenzodiazepine dimer. Upon binding AXL on cancer cells and internalization, the payload is released to form DNA interstrand cross-links and kill tumor cells. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05389462 | Phase 1 | Advanced Solid Tumors | Terminated | ADCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumors
See ADCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ADCT catalysts and pipeline →